MORRISTOWN, N.J.–(Company WIRE)–Melinta Therapeutics, LLC (“Melinta”), a industrial-stage organization giving progressive therapies for acute and lifestyle-threatening sicknesses, announces the appointment of Susan Blum as Main Economical Officer, productive July 1, 2021.
Ms. Blum has served as Melinta’s interim CFO, less than the management of President and Main Govt Officer Christine Ann Miller, since March 31, 2021, and she has been an integral chief on Melinta’s finance and accounting teams considering that 2016. Ms. Blum has a proven observe record of strengthening and executing company economic technique, efficiencies and controls for Melinta as properly as assorted firms prior to Melinta.
“Susan is a seasoned finance govt and our trusted husband or wife, with substantial know-how about our company, merchandise and markets. I’m the two proud and excited to welcome her as our CFO to assistance guide our firm forward with sustainable development,” Ms. Miller said. “As we keep on to construct a legendary foreseeable future, her expertise, as properly as her enthusiasm and devotion to Melinta, will be an incredible asset.”
Ahead of becoming a member of Melinta, Ms. Blum held management positions in finance and accounting at Textura, Orbitz All over the world, Side Biotech and PDL BioPharma. In these roles, some of her notable expertise contains directing international money processes, leading accounting capabilities through dynamic business circumstances, like preliminary and secondary general public choices, and directing monetary reporting and integration actions for mergers and acquisitions.
“I’m honored to direct Melinta’s economic team and functions at this enjoyable instant in the company’s journey,” Ms. Blum claimed. “Melinta is genuinely unparalleled in passion and function, and I’m fired up to continue to work with Christine and the relaxation of the team towards money sustainability while staying grounded in what matters most — the clients we serve.”
About Melinta Therapeutics
Melinta Therapeutics, LLC provides revolutionary therapies to men and women impacted by acute and existence-threatening ailments. Our portfolio currently incorporates five professional-phase antibiotics: Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to vendors and the patients they serve, we work to make certain that all men and women who need to have our therapies can receive them. We target our expanding portfolio on serving patients with an unmet need since that’s how we make the most significant effects. At Melinta, we’re visionaries devoted to innovation though keeping grounded in what matters most: clients. Pay a visit to www.melinta.com for a lot more data.
